Ornithine decarboxylase activity in human endometrium and endometrial cancer cells.
Ornithine decarboxylase (ODC) activities were significantly higher in proliferative endometrium during the estrogen-dominated follicular phase of the menstrual cycle than in secretory endometrium after the formation of the progesterone-secreting corpus luteum. The enzymatic activity was increased about fivefold by renewal of the medium during incubations of endometrial fragments or isolated endometrial glands. Endometrial adenocarcinoma cells (HEC-1, HEC-50), both in monolayers and suspension, also responded to medium renewal by increasing ODC activity about 10-fold after 4 h, with subsequent reduction to control levels after 7 h. These effects were blocked by actinomycin D and cycloheximide. Endometrial stromal cells exhibited highly variable ODC activities at different passages. Difluoromethylornithine (DFMO) and sodium molybdate had marked antiproliferative effects in HEC-50 cultures, reducing cell numbers to 10 to 20% of control values 11 d after plating and inhibiting ODC activity by approximately 80% on Day 7. The antiproliferative effect of DFMO, but not that of molybdate, was reversed by 10 microM putrescine, the product of ODC activity. In contrast to DFMO, molybdate had no effect on ODC activity of cell homogenates. Molybdate did not elicit antizyme formation in HEC-50 cells under conditions in which putrescine did. These results indicate that ODC activity, present in both epithelial and stromal cells, as shown analytically and also by autoradiography after labeling with [3H]DFMO, may be related to cell proliferation in vivo and that proliferation of human endometrial cancer cells in culture can be arrested by DFMO and by molybdate.
D000230:Adenocarcinoma / Q000201:enzymology; D002455:Cell Division / Q000187:drug effects; D002460:Cell Line; D003338:Corpus Luteum / Q000378:metabolism; D003513:Cycloheximide / Q000494:pharmacology; D003609:Dactinomycin / Q000494:pharmacology; D000518:Eflornithine; D004717:Endometrium / Q000201:enzymology*; D005260:Female; D005498:Follicular Phase; D006801:Humans; D008982:Molybdenum / Q000494:pharmacology; D009952:Ornithine / Q000031:analogs & derivatives / Q000494:pharmacology; D009955:Ornithine Decarboxylase / Q000032:analysis*; D011374:Progesterone / Q000378:metabolism; D011700:Putrescine / Q000494:pharmacology; D013997:Time Factors; D014594:Uterine Neoplasms / Q000201:enzymology*
D003609:Dactinomycin; D011374:Progesterone; D008982:Molybdenum; C024687:sodium molybdate(VI); D003513:Cycloheximide; D009952:Ornithine; D009955:Ornithine Decarboxylase; D011700:Putrescine; D000518:Eflornithine